Photoradiation therapy for cutaneous and subcutaneous malignancies.
Photoradiation therapy (PRT) using hematoporphyrin derivative (Hpd) as the photosensitizing agent is being developed for local treatment of a wide variety of malignant lesions including those involving the skin. The largest group of patients in this category are those with metastatic breast carcinoma in which 34/35 showed response to PRT. Other patients showing response to PRT are those with basal cell carcinoma, malignant melanoma, and squamous cell carcinoma.
D000368:Aged; D001943:Breast Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy; D002280:Basal Cell Carcinoma / Q000532:radiotherapy / Q000628:therapy; D005260:Female; D006415:Hematoporphyrins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008545:Melanoma / Q000532:radiotherapy / Q000628:therapy; D010789:Phototherapy; D012514:Sarcoma, Kaposi / Q000532:radiotherapy / Q000628:therapy; D012878:Skin Neoplasms / Q000532:radiotherapy / Q000628:therapy*
D006415:Hematoporphyrins